Latest News articles

More news articles

Sign-up benefits

Unlimited site access

Newswire

Sign up to receive a newswire from medicalphysicsweb and get the latest research and industry news delivered directly to your desk.

Free company listing

List your company on medicalphysicsweb free of charge, or become a Corporate Partner and take advantage of the enhanced benefits that this status offers. Make sure that potential customers can find the products that you sell.

Post your new products online

If you have a new product to promote and you want to tell people about it, post it on medicalphysicsweb. List your product free of charge or upgrade to Star Product status and benefit from guaranteed homepage exposure for one week.

Have your say

Sign up and get the opportunity to comment on our stories. We are always interested in your opinion and will be looking for your feedback.

Running an event?

Our events listing is free so, if you are organizing an event, post it on medicalphysicsweb.

Key suppliers

More companies

Corporate partners

For maximum exposure, become a Corporate partner. Contact our sales team.

Buyer’s Guide

Research

Jun 11, 2007

Radium-223 targets bone metastasis

The alpha-emitting radioactive isotope radium-223 (Ra) could form the basis of a promising new treatment for bone metastases, according to research just published online by The Lancet Oncology. A multicentre trial with prostate-cancer patients demonstrated that ²²³Ra is at least as effective as currently used radiopharmaceuticals and is also considerably less toxic (Lancet Oncol. DOI:10.1016/S1470-2045(07)70147-X).

We hope you've enjoyed the short summary of this article. To continue reading, and for unlimited access to all content on this site you will need to complete a short sign-up process. It's free of charge, and will only take a couple of minutes of your time. If you've signed up before, simply sign in below.